These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 20979652)

  • 1. Treatment options for patients with triple-negative breast cancer.
    Santana-Davila R; Perez EA
    J Hematol Oncol; 2010 Oct; 3():42. PubMed ID: 20979652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
    Nanda R
    Semin Oncol; 2011 Apr; 38(2):254-62. PubMed ID: 21421115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic options for triple-negative breast cancers with defective homologous recombination.
    Jaspers JE; Rottenberg S; Jonkers J
    Biochim Biophys Acta; 2009 Dec; 1796(2):266-80. PubMed ID: 19616605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel treatment approaches for triple-negative breast cancer.
    Telli ML; Ford JM
    Clin Breast Cancer; 2010; 10 Suppl 1():E16-22. PubMed ID: 20587403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The triple-negative subtype: new ideas for the poorest prognosis breast cancer.
    Curigliano G; Goldhirsch A
    J Natl Cancer Inst Monogr; 2011; 2011(43):108-10. PubMed ID: 22043054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple-negative breast cancer: disease entity or title of convenience?
    Carey L; Winer E; Viale G; Cameron D; Gianni L
    Nat Rev Clin Oncol; 2010 Dec; 7(12):683-92. PubMed ID: 20877296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological features and treatment strategy for triple-negative breast cancer.
    Yamamoto Y; Iwase H
    Int J Clin Oncol; 2010 Aug; 15(4):341-51. PubMed ID: 20632057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.
    Lee E; McKean-Cowdin R; Ma H; Spicer DV; Van Den Berg D; Bernstein L; Ursin G
    J Clin Oncol; 2011 Nov; 29(33):4373-80. PubMed ID: 22010008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
    Silver DP; Richardson AL; Eklund AC; Wang ZC; Szallasi Z; Li Q; Juul N; Leong CO; Calogrias D; Buraimoh A; Fatima A; Gelman RS; Ryan PD; Tung NM; De Nicolo A; Ganesan S; Miron A; Colin C; Sgroi DC; Ellisen LW; Winer EP; Garber JE
    J Clin Oncol; 2010 Mar; 28(7):1145-53. PubMed ID: 20100965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.
    Chen XS; Ma CD; Wu JY; Yang WT; Lu HF; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
    Tumori; 2010; 96(1):103-10. PubMed ID: 20437866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities.
    Conlin AK; Seidman AD
    Clin Breast Cancer; 2008 Jun; 8(3):215-23. PubMed ID: 18650151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple-negative breast cancer: risk factors to potential targets.
    Schneider BP; Winer EP; Foulkes WD; Garber J; Perou CM; Richardson A; Sledge GW; Carey LA
    Clin Cancer Res; 2008 Dec; 14(24):8010-8. PubMed ID: 19088017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer.
    Zhang J; Pei R; Pang Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Breast Cancer Res Treat; 2012 Apr; 132(2):421-8. PubMed ID: 21614564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
    Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
    Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple-negative breast cancer: epidemiology and management options.
    Dawood S
    Drugs; 2010 Dec; 70(17):2247-58. PubMed ID: 21080741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.
    Bouchalova K; Cizkova M; Cwiertka K; Trojanec R; Hajduch M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):13-7. PubMed ID: 19365520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological characteristics of triple-negative breast cancers.
    Sasaki Y; Tsuda H
    Breast Cancer; 2009; 16(4):254-9. PubMed ID: 19657711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between BRCA-associated breast cancer and age factors: an analysis of the Japanese HBOC consortium database.
    Okano M; Nomizu T; Tachibana K; Nagatsuka M; Matsuzaki M; Katagata N; Ohtake T; Yokoyama S; Arai M; Nakamura S
    J Hum Genet; 2021 Mar; 66(3):307-314. PubMed ID: 33046835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of triple-negative breast cancer.
    de Ruijter TC; Veeck J; de Hoon JP; van Engeland M; Tjan-Heijnen VC
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):183-92. PubMed ID: 21069385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.